Tag: M.W:500-600

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

A mixture of terephthalaldehyde (134 mg, 1.0 mmol) and triBoc-cyclam (250 mg, 500 mol) inDCM (10 mL) was stirred at ambient temperature for 2 h and then sodium triacetoxyborohydride (318mg, 1.5 mmol) was added. The mixture was stirred overnight at ambient temperature. The reaction wasquenched with aqueous NaHCO3, the layers were separated and the aqueous layer was extracted withdichloromethane. The combined organic layers were dried over anhydrous sodium sulfate andevaporated. The crude residue was purified by Combi-Flash (silica gel; ethyl acetate in hexanes) to givePKS8204 (198 mg, 64%) as a colorless gum, which turned into a fluffy solid under vacuum., 170161-27-0

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Article; Amor-Coarasa, Alejandro; Kelly, James M.; Singh, Pradeep K.; Ponnala, Shashikanth; Nikolopoulou, Anastasia; Williams, Clarence; Vedvyas, Yogindra; Jin, Moonsoo M.; David Warren; Babich, John W.; Molecules; vol. 24; 8; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

Example 6.1 Preparation of compounds 30a-b- General Procedure: HBTU (1 eq) and DIPEA (1.7 eq) were sequentially added to a suspension ofcompound 26 in CH2CI2 (concentration 1% w/v) and the mixture was keptunder stirring at room temperature for 30 min; phosphoethanolamine (DLPEn = 10 or DMPE n = 12) (1 eq) was then added and the mixture was maintained under stirring at room temperature for 24 h. The reactionmixture was sequentially washed with H20 (100 mL), acidified H20 (pH 4-5with HCI; 100 mL) and H20 (100 mL). The organic layer was dried(Na2S04), filtered and evaporated, and the so-obtained crude material waspurified by flash chromatography to obtain compounds 30a-b. Example 6.1a Preparation of 10-[(10R)-7-hydroxy-7-oxido-2,13-dioxo-10-[(1-oxododecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphatetracos-1-yl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid tris [(1,1-dimethyl)ethyl] ester 30aReagents: Compound 26 (968 mg; 1.69 mmol); 1,2-didodecanoyl-sn-glycero-3-phosphoethanolamine (980 mg; 1.69 mmol).Compound 30a (605 mg, 0.53 mmol); Yield 32%.Analytical dataHPLC-ELSD: 40.6% (area%)Mr: 1134.48 (C57H 108N5015P) 1H-and 13C-NMR and MS are compatible with the structure.

137076-54-1, 137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BRACCO IMAGING SPA; GHIANI, Simona; MAIOCCHI, Alessandro; BRIOSCHI, Chiara; VISIGALLI, Massimo; CABELLA, Claudia; MIRAGOLI, Luigi; WO2014/37498; (2014); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

Example 4- Synthesis of tri-tert-butyl 2,2′,2′-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate To a solution of product 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid (572.7 mg, 1 mmol) in dry DMF (15 mL), amino-maleimide 137 (483.3 mg, 1 mmol) was added with HATU (272 mg, 1.4 mmol) and DIPEA (360 muL, 1.84 mmol). The mixture was stirred overnight at room temperature. After removing the solvent under the vacuum, the crude product was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 90:10) to give compound tri-tert-butyl 2,2′,2′-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate as a white foam (396 mg, 57 %). Rf : 0.3 (CH2Cl2/MeOH, 90:10). 1H NMR (300MHz, CDCl3) delta 8.30 (b, 1H, NH), 6.86 (s,2H, H6′), 3.78-3.54 (br, 4H, H3′, H4′), 3.54 (br, 4H, H13, H1′), 3.48 (br, 4H, H8), 3.09-2.99 (m, 8H, H2, H3), 2.97-2.86 (m, 8H, H5, H6), 1.46 (s, 18H, H12), 1.45 (s, 9H, H17). 13C NMR (75MHz, CDCl3) delta 171.6 (C2′), 171.0 (C5′), 170.4 (C9, C14), 134.2 (C6′), 81.5 (C16), 81.3 (C11), 57.8 (C1′), 55.7-55.2 (C8, C13), 54.1-51.5 (C2, C3), 51.0-48.9 (C5, C6), 38.0 (C4′), 32.7 (C3′), 27.8 (C17), 27.6 (C12). MS (ESI) : m/z 695 [M + H]+.

137076-54-1, 137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Institut Curie; Centre National de la Recherche Scientifique; The designation of the inventor has not yet been filed; EP2740491; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135616-40-9,(R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine,as a common compound, the synthetic route is as follows.,135616-40-9

5.46 g (0.01 mol) of (R,R)-2,2′-[1,2-cyclohexanediyl)bis(nitrilomethylidyne)]-bis[4,6-di-tert-butyl)phenol] are initially charged in 50 ml of ethanol and admixed with 1.14 g (0.0045 mol) of vanadyl sulfate pentahydrate. After three hours under reflux and complete conversion (TLC monitoring), the solvent is distilled off, the residue taken up in 200 ml of dichloromethane and the solution washed with 100 ml of water. After phase separation, drying of the solution with sodium sulfate and distilling off the solvent, 5.4 g of bright green, amorphous powder (yield: 96% of theory, based on a vanadium:salen ligand ratio of 1:2) are obtained.

The synthetic route of 135616-40-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Kirschbaum, Bettin; Fell, Rainer; US2004/236129; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135616-40-9,(R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine,as a common compound, the synthetic route is as follows.

5,46 G (0,01 mol) (R, R)-2, 2′- [1, 2-Cyclohexandiyl) bis (nitrilomethylidyn)] bis [4,6-di- tert.-butyl)-phenol] (Illa) werden in 25 ml THF vorgelegt und mit 1,26 g (0,005 mol) VANADYLSULFAT-PENTAHYDRAT in 25 ml Ethanol versetzt. Nach drei Stunden unter Rueckfluss wird das Loesungsmittel abdestilliert, der Rueckstand in 50 mi Dichlormethan aufgenommen und die Loesung mit 300 ml Wasser gewaschen. Nach Phasentrennung, Trocknen der Loesung mit Natriumsulfat und Abdestillieren des Loesungsmittels erhaelt man 3,6 g gruenes, amorphes Pulver. Zusammensetzung des Gemischs nach HPLC (Gew. -%) : Komponente (I) : (II) : (III) =43% : 13% : 44 %.

135616-40-9, 135616-40-9 (R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine 2733339, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; CLARIANT GMBH; WO2004/55028; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

solution of DOTA tri-t-butyl ester (0.972 g, 1.70 mmol), HBTU (0.772 g, 2.04 mmol), HOBt (0.312 g, 2.04 mmol), and DIEA (0.59 niL, 5.9 mmol) in anhydrous DMF (8.0 mL) was stirred at room temperature under nitrogen for 20 minutes. The product of Part B (1.38 g, 1.70 mmol) was added in one portion. Additional HBTU (0.772 g, 2.04 mmol) was added after 1 hour and the reaction was stirred for an additional 3 hours. The reaction mixture was quenched with 10% citric acid (20 mL) and diluted with dichloromethane (30 mL). The aqueous layer was extracted with dichloromethane (3 x 30 mL). The combined organic extracts were washed consecutively with 10% citric acid (30 mL), saturated NaHCO3 (3 x 30 mL), and saturated NaCl (3 x 30 mL), dried (MgSO4), filtered, and concentrated to give a yellow oil. The oil was purified by flash chromatography over silica gel, eluting with ethyl acetate to give the title compound as a colorless oil (0.746 g, 48%). 1H NMR (4:1 CDCl3:DMSO-<4): delta 7.54 (m, 2H), 7.41 (m, 2H), 7.17 (m, 2H), 7.08 (m, 2H), 4.15 (d, 2H), 4.02 (m, IH), 2.97 (m, 2H), 2.68-2.45 (m, 24H), 2.00 (t, 2H), 1.44 (t, 2H), 1.30-1.11 (m, 31H). MS (ESI): 461.9 (100, M+2H), 922.5 (80, M+H)., 137076-54-1

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; BRISTOL-MYERS SQUIBB PHARMA COMPANY; WO2007/5491; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

135616-36-3, (S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

8,0 g (0,015 mol) (S, S)-2, 2 – [1, 2-CYCLOHEXANDIYL) bis (nitrilomethylidyn)] bis [4,6-di- tert.-butyl)-phenol] werden in 200 ml Ethanol vorgelegt und mit 2,5 g (0,01 mol) Vanadylsulfat-Pentahydrat versetzt. Nach zwei Stunden unter Rueckfluss wird das Loesungsmittel abdestilliert, der Rueckstand in 400 ML Dichlormethan aufgenommen und die Loesung mit 200 ml Wasser gewaschen. Nach Phasentrennung, Trocknen der Loesung mit Natriumsulfat und Abdestillieren des Loesungsmittels erhaelt man 8,2 g gruenes, amorphes Pulver. Zusammensetzung des Gemischs nach HPLC (Gew. -%) : Komponente (I) : (X) : (III) =85% : 15% : 0%. [alpha D20 = +200 (c = 0,01, Chloroform)., 135616-36-3

As the paragraph descriping shows that 135616-36-3 is playing an increasingly important role.

Reference£º
Patent; CLARIANT GMBH; WO2004/55028; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

Example 7-Synthesis of tri-tert-butyl 2,2′,2′-(10-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate The procedure that was followed was described in . Compound 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid (400 mg, 0.70 mmol), N-hydroxysuccinimide (90.4 mg, 0.78 mmol, 1.1 equiv.), and Obenzotriazol- 1-yl-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU) (296 mg, 0.78 mmol, 1.1 equiv.) were dissolved in 10 mL of acetonitrile. The reaction was stirred at room temperature for 24 hr. After removing the solvent under vaccum, the crude product was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 85:15) to give compound tri-tert-butyl 2,2′,2′-(10-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate as a white foam (404 mg, 86 %). Rf : 0.3 (CH2Cl2/MeOH, 85:15). 1H NMR (300MHz, CDCl3) delta 3.51 (br, 4H, H8), 3.54 (br, 4H, H13, H1′), 3.32-3.26 (m, 4H, H6), 3.08-2.99 (m, 4H, H5), 2.97-2.86 (m, 8H, H2, H3), 2.85 (s, H4′), 1.46 (s, 18H, H12), 1.45 (s, 9H, H17). 13C NMR (75MHz, CDCl3) delta 173.4 (C9, C14), 173.1 (C2′), 169.9 (C3′), 82.6 (C16), 82.4 (C11), 55.8 (C8), 55.7 (C13), 54.2 (C1′), 54.1-51.5 (C2, C3), 51.0-48.9 (C5, C6), 27.8 (C17), 27.6 (C12). 25.6 (C4′) MS (Cl/NH3) m/z 692 [M + H]+, 137076-54-1

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; Institut Curie; Centre National de la Recherche Scientifique; The designation of the inventor has not yet been filed; EP2740491; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

(2)1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid tri-tert-butyl (8.3 mg)In DMF (0.1 mL) and DIEA (10 [mu] L)A solution of HBTU (5.5 mg) in DMF (100 muL) was added, (N1) (4.6 mg) in DMF (200 muL) and DIEA (20 muL)And the mixture was stirred at room temperature for 1.5 hours. Water (100 muL) was added,Purification by preparative HPLC gave (N 2) (3.5 mg).

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; Fujifilm RI Pharma Co., Ltd.; Hirofumi, Fukunaga; Do En, Hiroyuki; Hino, Akihiro; Oshikiri, Shinobu; Chou, Rumpf; (131 pag.)JP2016/183151; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.135616-40-9,(R,R)-(-)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine,as a common compound, the synthetic route is as follows.

5,46 g (0,01 mol) (R, R)-2, 2 – [1, 2-CYCLOHEXANDIYL) bis (nitrilomethylidyn)] bis [4,6-di- TERT.-BUTYL)-PHENOL] (Illa) werden in 50 ml Dichlormethan vorgelegt und mit 1,26 g (0,005 mol) VANADYLSULFAT-PENTAHYDRAT in 50 ml Dichlormethan versetzt. Nach 21 Stunden unter Rueckfluss wird das Loesungsmittel abdestilliert, und der Rueckstand per HPLC untersucht. Zusammensetzung des Gemischs nach HPLC (Gew. -%) : Komponente (I) : (11) : (LUI) =0% : 0% 100%.

135616-40-9, As the paragraph descriping shows that 135616-40-9 is playing an increasingly important role.

Reference£º
Patent; CLARIANT GMBH; WO2004/55028; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI